RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: Transcutaneous Electrical Stimulation for Obstructive Sleep Apnea

* The aim of this study is to assess the impact of transcutaneous electrical stimulation on polysomnographic findings in obstructive sleep apnea patients. * The hypothesis of the present study is that nocturnal delivery of transcutaneous electrical stimulation of the pharyngeal dilators, in particular the genioglossus, may help in treating the functional loss of the neuromuscular tone with sleep onset to keep the Upper airway patent during sleep which would reduce the severity of OSA as measured by the apnea-hypopnea-index (AHI), so representing an alternative and better-tolerated approach compared to usual care with CPAP.

Official registry: https://clinicaltrials.gov/study/NCT07891702 · Mansoura University · enrollment listed as 50

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Transcutaneous Electrical Stimulation. The registry lists allocation as na. * The aim of this study is to assess the impact of transcutaneous electrical stimulation on polysomnographic findings in obstructive sleep apnea patients.

They plan to enroll about 50 people at Al Mansurah. Taking part typically means using or being fitted with a device plus check-ins.

Official title (unrewritten)

Effect of Transcutaneous Electrical Stimulation on Polysomnographic Parameters in Patients With Obstructive Sleep Apnea: A Prospective Interventional Study

Interventions: Transcutaneous Electrical Stimulation

Primary outcome (registry wording): Change in Apnea-Hypopnea Index (AHI)

Who it is for (from inclusion criteria)

Ages 18 Years to any
1 - Adult patients aged 18 years or older. 2- Male or female patients diagnosed with obstructive sleep apnea by baseline overnight polysomnography

Who the registry excludes

Patients with central sleep apnea or predominantly central sleep-disordered breathing
Patients with significant unstable cardiovascular or respiratory disease that may increase the risk of participation
Patients with implanted electronic devices, such as pacemakers or implantable cardioverter-defibrillators
Patients with skin lesions, infection, irritation, or other abnormalities at the intended electrode application sites
Patients with neurological or neuromuscular disorders that significantly affect upper airway muscle function
Patients with a history of upper airway surgery that substantially alters upper airway anatomy, if this may interfere with study assessment
Patients unable to tolerate electrical stimulation or complete the required polysomnography sessions

Public study contact (from the registry)

Mohammed Shehta, Associate professor-chest med.

+201004344106

dr_mshehta@mans.edu.eg

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Mansoura University — Al Mansurah, Dakahlia Governorate, Egypt (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland

Development of a Wearable Point of Care Monitoring Device for Pediatric Obstructive Sleep Apnea

Background: Obstructive sleep apnea (OSA) occurs when the blockage of the airway causes a person to stop breathing involuntarily for 10 seconds or more throughout the night during sleep. Pediatric OSA can be especially concerning and can have long-term effects.

NCT05052216 · Official ClinicalTrials.gov record · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

RecruitingNot a traditional drug phaseSan Diego, California

Not a traditional drug phase: Positive Airway Pressure Device for Post Traumatic Stress Disorder

Substance use disorder (SUD) and posttraumatic stress disorder (PTSD) frequently co-occur and having both disorders is associated with greater psychological and functional impairment than having either disorder alone. This is especially true in residential settings where both disorders are more severe than outpatient settings.

NCT05156112 · Official ClinicalTrials.gov record · VA Office of Research and Development

RecruitingNot a traditional drug phaseBeijing

Not a traditional drug phase: Level III portable sleep study for Sleep Apnea

The investigators propose a prospective, watch-and-measure (no experimental treatment required) study to determine the impact of OSA and associated physiological parameters on clinical outcomes in patients with pulmonary hypertension. The prevalence, phenotypes, and predictors of OSA in the setting of pulmonary hypertension will also be investigated.

NCT05595200 · Official ClinicalTrials.gov record · Chinese Pulmonary Vascular Disease Research Group

FAQ about this NCT record

Is NCT07891702 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07891702?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07891702?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary